Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Orr

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Conservation Biology : the Journal of the Society for Conservation Biology|December 7, 2010
Ecological literacyD W Orr
Trends in Ecology & Evolution|January 18, 2011
Ecological intelligenceD W Orr
Mental Hygiene|October 29, 2010
The veteran and his neuropsychiatric diagnosisD W ORR
Cancer Treatment Reports|May 1, 1985
Phase I study of N-methylformamide in patients with advanced cancerD S Ettinger, D W Orr, A P Rice, et al.
Seminars in Surgical Oncology|January 1, 1988
Principles of biotherapy and its application to the treatment of disseminated renal cancerT E O'Connor, W H West, G D Marshall, et al.
Journal of the National Cancer Institute|July 6, 1988
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activityE K Rowinsky, D A Noe, D W Orr, et al.
The International Journal of Biological Markers|April 1, 1989
Individually specified drug immunoconjugates in cancer treatmentR K Oldham, M Lewis, D W Orr, et al.
Molecular Biotherapy|January 1, 1988
Adriamycin custom-tailored immunoconjugates in the treatment of human malignanciesR K Oldham, M Lewis, D W Orr, et al.
The New England Journal of Medicine|April 9, 1987
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancerW H West, K W Tauer, J R Yannelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trialR O Dillman, R K Oldham, K W Tauer, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Conservation Biology : the Journal of the Society for Conservation Biology|December 7, 2010
Ecological literacyD W Orr
Trends in Ecology & Evolution|January 18, 2011
Ecological intelligenceD W Orr
Mental Hygiene|October 29, 2010
The veteran and his neuropsychiatric diagnosisD W ORR
Cancer Treatment Reports|May 1, 1985
Phase I study of N-methylformamide in patients with advanced cancerD S Ettinger, D W Orr, A P Rice, et al.
Seminars in Surgical Oncology|January 1, 1988
Principles of biotherapy and its application to the treatment of disseminated renal cancerT E O'Connor, W H West, G D Marshall, et al.
Journal of the National Cancer Institute|July 6, 1988
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activityE K Rowinsky, D A Noe, D W Orr, et al.
The International Journal of Biological Markers|April 1, 1989
Individually specified drug immunoconjugates in cancer treatmentR K Oldham, M Lewis, D W Orr, et al.
Molecular Biotherapy|January 1, 1988
Adriamycin custom-tailored immunoconjugates in the treatment of human malignanciesR K Oldham, M Lewis, D W Orr, et al.
The New England Journal of Medicine|April 9, 1987
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancerW H West, K W Tauer, J R Yannelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trialR O Dillman, R K Oldham, K W Tauer, et al.
Pageof 2